^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    VENTANA CLDN18 (43-14A) Assay

    Company:
    Roche
    Type:
    FDA Approved
    Related tests:
    Evidence Level:
    Sensitive: A1 - Approval

    [CLDN18.2 positive + HER-2 negative-Gastroesophageal Junction Adenocarcinoma-zolbetuximab-clzb]

    Source:
    Precision Medicine Online
    Test:

    VENTANA CLDN18 (43-14A) Assay

    Title:
    FDA Approves Astellas' Vyloy, Chemo in First-Line CLDN18.2-Positive Gastric Cancer With Roche CDx
    Published date:
    10/18/2024
    Excerpt:
    The US Food and Drug Administration on Friday approved Astellas' Vyloy (zolbetuximab-clzb) with chemotherapy as a first-line treatment for patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive.
    Evidence Level:
    Sensitive: A1 - Approval

    [CLDN18.2 positive + HER-2 negative-Gastric Cancer-zolbetuximab-clzb]

    Source:
    Precision Medicine Online
    Test:

    VENTANA CLDN18 (43-14A) Assay

    Title:
    FDA Approves Astellas' Vyloy, Chemo in First-Line CLDN18.2-Positive Gastric Cancer With Roche CDx
    Published date:
    10/18/2024
    Excerpt:
    The US Food and Drug Administration on Friday approved Astellas' Vyloy (zolbetuximab-clzb) with chemotherapy as a first-line treatment for patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive.